Sexually dimorphic mammalian tissues, including sexual organs and the brain, contain stem cells that are directly or indirectly regulated by sex hormones [1] [2] [3] [4] [5] [6] . An important question is whether stem cells also exhibit sex differences in physiological function and hormonal regulation in tissues that do not show sex-specific morphological differences. The terminal differentiation and function of some haematopoietic cells are regulated by sex hormones 7-10 , but haematopoietic stem-cell function is thought to be similar in both sexes. Here we show that mouse haematopoietic stem cells exhibit sex differences in cell-cycle regulation by oestrogen. Haematopoietic stem cells in female mice divide significantly more frequently than in male mice. This difference depends on the ovaries but not the testes. Administration of oestradiol, a hormone produced mainly in the ovaries, increased haematopoietic stem-cell division in males and females. Oestrogen levels increased during pregnancy, increasing haematopoietic stem-cell division, haematopoietic stemcell frequency, cellularity, and erythropoiesis in the spleen. Haematopoietic stem cells expressed high levels of oestrogen receptor-a (ERa). Conditional deletion of ERa from haematopoietic stem cells reduced haematopoietic stem-cell division in female, but not male, mice and attenuated the increases in haematopoietic stem-cell division, haematopoietic stem-cell frequency, and erythropoiesis during pregnancy. Oestrogen/ERa signalling promotes haematopoietic stem-cell self-renewal, expanding splenic haematopoietic stem cells and erythropoiesis during pregnancy.
Sexually dimorphic mammalian tissues, including sexual organs and the brain, contain stem cells that are directly or indirectly regulated by sex hormones [1] [2] [3] [4] [5] [6] . An important question is whether stem cells also exhibit sex differences in physiological function and hormonal regulation in tissues that do not show sex-specific morphological differences. The terminal differentiation and function of some haematopoietic cells are regulated by sex hormones 7-10 , but haematopoietic stem-cell function is thought to be similar in both sexes. Here we show that mouse haematopoietic stem cells exhibit sex differences in cell-cycle regulation by oestrogen. Haematopoietic stem cells in female mice divide significantly more frequently than in male mice. This difference depends on the ovaries but not the testes. Administration of oestradiol, a hormone produced mainly in the ovaries, increased haematopoietic stem-cell division in males and females. Oestrogen levels increased during pregnancy, increasing haematopoietic stem-cell division, haematopoietic stemcell frequency, cellularity, and erythropoiesis in the spleen. Haematopoietic stem cells expressed high levels of oestrogen receptor-a (ERa). Conditional deletion of ERa from haematopoietic stem cells reduced haematopoietic stem-cell division in female, but not male, mice and attenuated the increases in haematopoietic stem-cell division, haematopoietic stem-cell frequency, and erythropoiesis during pregnancy. Oestrogen/ERa signalling promotes haematopoietic stem-cell self-renewal, expanding splenic haematopoietic stem cells and erythropoiesis during pregnancy.
A fundamental question in stem-cell biology concerns the extent to which stem cells are regulated by long-range signals to ensure that stem-cell function within individual tissues is integrated with the overall physiological state 11 . For example, stem cells in the intestine, central nervous system and germ line are regulated by insulin and nutritional status [12] [13] [14] [15] [16] [17] . Among haematopoietic cells oestrogen regulates proliferation, survival, differentiation and cytokine production by lymphoid and myeloid cells 10, 18, 19 , and induces apoptosis in erythroid cells by inhibiting GATA1 (refs 20, 21) . This raises the question of whether sex hormones also regulate haematopoietic stem cells.
Comparing 8-10-week-old male and female mice, we observed no significant differences in the frequency (Fig. 1a ) or total numbers (Fig. 1b , c) of CD150 1 CD48 2 Lin 2 Sca-1 1 c-kit 1 haematopoietic stem cells or CD150 2 CD48 2 Lin 2 Sca-1 1 c-kit 1 multipotent progenitors (MPPs) 22 , or in the percentage of bone marrow cells that incorporated a 10-day pulse of 5-bromodeoxyuridine (BrdU; Fig. 1d ). However, a significantly higher percentage of haematopoietic stem cells and MPPs incorporated BrdU in female as compared to male mice (Fig. 1d ). Because the haematopoietic stem cells had incorporated BrdU while remaining in the haematopoietic stem-cell pool, haematopoietic stem cells undergo more frequent self-renewing divisions in female mice than in male mice.
To test this using an independent approach we treated 4-6-weekold Rosa26-rtTA; tetO-H2B-GFP mice 23 with doxycycline for 6 weeks to induce histone H2B-GFP expression and then chased for 12 weeks without doxycycline to assess the rate of H2B-GFP dilution as a result of cell division. After 6 weeks of doxycycline treatment, haematopoietic stem cells, MPPs and whole bone marrow (WBM) cells in male and female mice were strongly and uniformly labelled with H2B-GFP ( Fig. 1e ). However, after the 12-week chase almost all bone marrow cells lost H2B-GFP expression in male and female mice ( Fig. 1e , f). As expected 23, 24 , haematopoietic stem cells and MPPs retained substantial frequencies of H2B-GFP high cells that were relatively quiescent during the chase period ( Fig. 1e , f). Consistent with the higher rate of BrdU incorporation in female haematopoietic stem cells, significantly (P , 0.005) lower percentages of haematopoietic stem cells and MPPs retained high levels of H2B-GFP in female as compared to male mice ( Fig. 1e , f). Haematopoietic stem cells and MPPs thus divide more frequently in female as compared to male mice.
Ovariectomy, but not castration, significantly reduced the percentage of haematopoietic stem cells and MPPs that incorporated a 10-day pulse of BrdU ( Fig. 2a ). Indeed, ovariectomy reduced haematopoietic stem-cell and MPP division in females to male levels ( Fig. 2a ). Castration or ovariectomy did not affect the numbers of haematopoietic stem cells or MPPs in the bone marrow (Extended Data Fig. 1a ) and produced only minor changes in the gross lineage composition of bone marrow cells (Extended Data Fig. 1b ). The rate of haematopoietic stem-cell division in female mice is therefore increased by signals from the ovary.
To test whether female sex hormones can affect haematopoietic stem-cell cycling we administered oestradiol (E2; 2 mg day 21 ), progesterone (P; 1 mg day 21 ) 5 , or oestradiol with progesterone (E21P) to young adult male and female mice for 1 week along with BrdU for the last 3 days. This significantly increased oestrogen and/or progesterone levels in both male and female mice (Extended Data Fig. 3a , b) without exceeding the physiological levels observed during pregnancy. These treatments did not affect bone marrow or spleen cellularity ( Fig. 2b) or haematopoietic stem-cell frequency ( Fig. 2c ), but E2 induced erythropoiesis in the spleen (Extended Data Fig. 2d ). Treatment with E2 or E21P, but not P alone, significantly increased BrdU incorporation by haematopoietic stem cells, but not by unfractionated bone-marrow cells, in both male and female mice ( Fig. 2d ).
E2 treatment increased BrdU incorporation by haematopoietic stem cells in castrated and ovariectomized mice, indicating that E2 acts independently of the gonads ( Fig. 2e ). E2 treatment also increased the frequency of Ki67 1 haematopoietic stem cells ( Fig. 2f and Extended Data Fig. 4a ). E2 treatment significantly reduced the frequency of haematopoietic stem cells that retained H2B-GFP in Rosa26-rtTA; tetO-H2B-GFP mice (Extended Data Fig. 4b, c ). In contrast, treatment with dihydrotestosterone did not affect BrdU incorporation by male or female haematopoietic stem cells ( Fig. 2g ) or haematopoietic stem-cell frequency in bone marrow ( Fig. 2h ).
Consistent with the observation that oestrogen induces apoptosis in erythroid progenitors 20 , we observed an increased frequency of annexin-V 1 Ter119 1 cells in female as compared to male bone marrow (Extended Data Fig. 5a ). This appeared to be offset by increased generation of megakaryocyte-erythroid progenitors (MEPs) in female mice (Extended Data Fig. 5b ). Neither MEPs nor Ter119 1 cells exhibited differences in cell-cycle distribution between males and females (Extended Data Fig. 5c ). Given that MEPs may arise directly from the asymmetric division of HSCs 25 , these observations raise the possibility that the increased frequency of MEPs in female mice reflects increased asymmetric selfrenewal of female haematopoietic stem cells in response to oestrogen.
We treated mice for 14 days with the aromatase inhibitor anastrozole, which reduces oestrogen levels 26 . Anastrozole did not significantly affect bone marrow cellularity ( Fig. 3a ) or lineage composition (Extended Data Fig. 6a ), but slightly reduced haematopoietic stem-cell frequency in female mice (Fig. 3b ). Anastrozole did not significantly affect BrdU incorporation (during the last 10 days of anastrozole) by whole bone marrow cells or MPPs in male or female mice, but did significantly reduce BrdU incorporation by female haematopoietic stem cells (P , 0.05, Fig. 3c ). Treatment with the progesterone receptor antagonist RU486 had no effect on bone marrow or spleen cellularity, haematopoietic stem-cell frequency, or BrdU incorporation (Extended Data Fig. 3d-f ). These results indicated that endogenous oestrogen increases haematopoietic stem-cell division in female mice.
Haematopoietic stem cells and MPPs from male and female mice expressed high levels of oestrogen receptor-a (ERa; encoded by Esr1) (Fig. 3d, e ). However, haematopoietic stem cells expressed little or no ERb (encoded by Esr2), progesterone receptor (Pgr), or androgen receptor (Ar) ( Fig. 3d ). To assess the roles of ERa and ERb in haematopoietic stem-cell regulation we treated male mice with the ERa agonist propylpyrazoletriol (PPT) or the ERb agonist diarylpropionitrile (DPN) 27 for 2 weeks along with BrdU for the last 10 days. PPT and DPN did not affect bone marrow or spleen cellularity, or the frequencies of haematopoietic stem cells and MPPs (Extended Data Fig. 7a, b ). PPT, but not DPN, significantly increased erythropoiesis in the bone marrow and spleen (Extended Data Fig. 7c ) as well as BrdU incorporation by haematopoietic stem cells (Extended Data Fig. 7d ), indicating that oestrogen effects on haematopoietic stem cells are mediated mainly by ERa. Consistent with this conclusion, germline Esr1-deficient mice of both sexes had normal bone marrow cellularity and lineage composition . e, Administering E2 to castrated or ovariectomized mice significantly increased haematopoietic stem-cell division by BrdU incorporation (n 5 5). f, Administering E2 to male mice increased the frequency of haematopoietic stem cells positive for Ki67 (n 5 3). g, h, Administering dihydrotestosterone (DHT) for 7 days did not affect haematopoietic stem-cell division or haematopoietic stem-cell frequency (n 5 4 mice per treatment in 4 independent experiments). Data represent mean 6 standard deviation; *P , 0.05; **P , 0.005; ***P , 0.0005 by Student's t-test. NS, not significant. 
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(Extended Data Fig. 6b, d) , as well as normal haematopoietic stem-cell and MPP frequency (Extended Data Fig. 6c ), but significantly reduced BrdU incorporation into haematopoietic stem cells in female but not male mice (Fig. 3f ).
To test whether ERa acts autonomously in haematopoietic stem cells we conditionally deleted Esr1 from haematopoietic cells. Mx1-cre;
Esr1 fl/fl mice and Esr1 fl/fl controls were treated with polyinosinic:polycytidylic acid (poly(I:C); four doses of 10 mg per 20 g body mass per day over 8 days) to induce Mx1-cre expression, then 19-21 days after poly(I:C) treatment we pulsed with BrdU for 10 days. Conditional deletion of Esr1 from haematopoietic cells significantly reduced BrdU incorporation into haematopoietic stem cells in female, but not male, mice (Fig. 3g ).
Seven days of E2 significantly increased BrdU incorporation (3-day pulse) by haematopoietic stem cells from Esr1 fl/fl controls but not Mx1-cre; Esr1 fl/fl mice (Fig. 3h ). Similar results were obtained using Vav1-cre; Esr1 fl/fl mice (Fig. 3i ), indicating that Esr1-deficient haematopoietic stem cells are not capable of responding to exogenous oestrogen.
To test whether E2 acts directly on haematopoietic stem cells, we competitively transplanted 10 6 CD45.2 1 Vav1-cre; Esr1 fl/fl bone marrow cells along with 10 6 CD45.1 1 bone marrow cells into irradiated mice. Fifteen weeks later we treated the mice with either E2 or vehicle for 7 days along with BrdU for the last 3 days. E2 treatment did not significantly affect BrdU incorporation by wild-type or Esr1-deficient bone marrow cells (Fig. 3j ). E2 treatment did significantly increase BrdU incorporation by wild-type haematopoietic stem cells but not by Esr1deficient haematopoietic stem cells in the same mice (Fig. 3j ). This demonstrates that E2 acts directly on haematopoietic stem cells, rather than acting indirectly by stimulating secondary signals from other haematopoietic stem cells. Consistent with this, addition of E2 to cultured haematopoietic stem cells significantly increased BrdU incorporation by wild-type haematopoietic stem cells from male and female mice but not Esr1-deficient haematopoietic stem cells (Fig. 3k ). 
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Gene set enrichment analysis (GSEA) revealed significant enrichment of cell-cycle genes and genes with E2F1 motifs in haematopoietic stem cells from mice treated with E2 for 1 week (Extended Data Fig. 8a, b ). ERa signalling may therefore promote haematopoietic stem-cell division by activating E2Fs.
Oestrogen levels increase in females during ovulation and pregnancy 28 . Relative to normal female mice, pregnant mice exhibited significantly increased cellularity, erythropoiesis and myelopoiesis in the spleen (Fig. 4a, b ) as well as more haematopoietic stem cells in the bone marrow and spleen (Fig. 4c) . A 24-h pulse of BrdU to pregnant mothers on day 13.5 of gestation revealed significant increases in proliferation among haematopoietic stem cells, whole bone marrow cells and splenocytes in pregnant as compared to normal female mice (Fig. 4d) . As expected 28 , serum E2 levels increased significantly in pregnant as compared to control mice (Fig. 4e) .
Deletion of Esr1 from haematopoietic cells in Mx1-cre; Esr1 fl/fl mice significantly reduced cellularity (Fig. 4a) , erythropoiesis ( Fig. 4b) and haematopoietic stem-cell numbers (Fig. 4c ) in the spleens of pregnant mice relative to pregnant Esr1 fl/fl controls. Deletion of Esr1 from haematopoietic cells also significantly reduced BrdU incorporation into haematopoietic stem cells in the bone marrow and spleen of pregnant mice (Fig. 4d ). Esr1 deletion from haematopoietic cells in pregnant mice did not block the increase in haematopoietic stem-cell frequency in the bone marrow but nearly eliminated the increase in haematopoietic stem-cell frequency in the spleen (Fig. 4c ). This indicates that oestrogen is not the only factor that increases haematopoietic stem-cell activity in pregnant mice but that it is critical for the mobilization of proliferating haematopoietic stem cells to the spleen and for the expansion of splenic erythropoiesis.
The increase in spleen cellularity and erythropoiesis during pregnancy may also occur in humans, which exhibit increased spleen size during pregnancy 29, 30 . There may be many unexplored mechanisms by which systemic signals modulate the function of stem cells within individual tissues in response to physiological change.
METHODS SUMMARY
Specific mouse alleles used in this study are referenced in Methods. Mice were housed in AAALAC-accredited, specific-pathogen-free animal care facilities at the University of Michigan (UM), Baylor College of Medicine (BCM), or UT Southwestern Medical Center (UTSW). All procedures were approved by the UM, BCM and UTSW Institutional Animal Care and Use Committees. For hormonal treatment, mice were injected subcutaneously with 100 ml of corn oil containing 2 mg oestradiol (Sigma), 1 mg progesterone (Sigma) 5 , or 100 mg of dihydrotestosterone (Steraloids). 50 mg of anastrozole (Sigma) dissolved in PBS was given intraperitoneally. RU486, PPT and DPN (all from Sigma) dissolved in corn oil were administered subcutaneously at 5 mg kg 21 . Poly(I:C) (Amersham) was re-suspended in PBS at 50 mg ml 21 , and 0.5 mg g 21 of body mass was injected intraperitoneally every other day for 6 days. Female mice were mated with male mice 1 week after the last injection.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Mice. The mouse alleles used in this study were Rosa26-rtTA/tetO-H2B-GFP (ref. 23) , germline Esr1-deficient 31 , Mx1-cre (ref. 32 ), Vav1-cre (ref. 33) , and Esr1 fl (ref. 34) . Most studies of haematopoietic stem-cell frequency and cycling used young adult C57BL/Ka-Thy-1.1 (CD45.2) mice (8-12 weeks of age). C57BL/ Ka-Thy-1.2 (CD45.1) mice were used in transplantation experiments. Mice were housed in AAALAC-accredited, specific-pathogen-free animal care facilities at the University of Michigan (UM), at Baylor College of Medicine (BCM), or UT Southwestern Medical Center (UTSW). All procedures were approved by the UM, BCM and UTSW Institutional Animal Care and Use Committees. Hormone and poly(I:C) treatments. Mice were injected subcutaneously with 100 ml of corn oil containing 2 mg oestradiol (Sigma) and/or 1 mg progesterone (Sigma) 5 . 100 mg of dihydrotestosterone (Steraloids) in corn oil was administered subcutaneously 35 . 50 mg of anastrozole (Sigma) dissolved in PBS was given intraperitoneally. RU486, PPT and DPN (all from Sigma) dissolved in corn oil were administered subcutaneously at 5 mg kg 21 . Poly(I:C) (Amersham) was re-suspended in PBS at 50 mg ml 21 , and mice were injected intraperitoneally with 0.5 mg g 21 of body mass every other day for 6 days. Note that the biological effect of poly(I:C) varies with polymer length and manufacturer such that doses must be optimized with each batch to obtain complete recombination without inducing haematopoietic stem-cell cycling. Females were mated with male mice 1 week after the last injection. Statistical methods. Multiple independent experiments were performed to verify the reproducibility of all experimental findings. Group data always represent mean 6 standard deviation. Unless otherwise indicated, two-tailed Student's t-tests were used to assess statistical significance. No randomization or blinding was used in any experiments. Experimental mice were not excluded from analysis in any experiments. Sample sizes were selected on the basis of previous experience with the degree of variance in each assay. Cell-cycle analysis. BrdU incorporation in vivo was measured by flow cytometry using the APC BrdU Flow Kit (BD Biosciences). Mice were given an intraperitoneal injection of 1 mg of BrdU (Sigma) per 6 g of body mass in PBS and maintained on 1 mg ml 21 BrdU in the drinking water for up to 10 days. Flow cytometry and haematopoietic stem-cell isolation. Bone marrow cells were either flushed from the long bones (tibias and femurs) or isolated by crushing the long bones (tibias and femurs), pelvic bones and vertebrae with mortar and pestle in Hank's buffered salt solution (HBSS) without calcium and magnesium, supplemented with 2% heat-inactivated bovine serum (Gibco). Cells were triturated and filtered through nylon screen (100 mm, Sefar America) or a 40 mm cell strainer (Fisher Scientific) to obtain a single-cell suspension. For isolation of CD150 1 CD48 2 Lin 2 Sca-1 1 c-kit 1 haematopoietic stem cells, bone marrow cells were incubated with PE-Cy5-conjugated anti-CD150 (TC15-12F12.2; BioLegend), PE-conjugated anti-CD48 (HM48-1; BioLegend), APC-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-c-kit (2B8) antibody, in addition to antibodies against the following FITC-conjugated lineage markers: CD41 (MWReg30; BD Biosciences), Ter119, B220 (6B2), Gr1 (8C5), CD2 (RM2-5), CD3 (KT31.1) and CD8 (53-6.7). For isolation of CD34 2 CD16/32 2 Lin 2 Sca-1 2 ckit 1 MEPs, CD34 1 CD16/32 2 Lin 2 Sca-1 2 c-kit 1 CMPs, and CD34 1 CD16/32 1 Lin 2 Sca-1 2 c-kit 1 GMPs, bone marrow cells were incubated with FITC-conjugated anti-CD34 (RAM34; eBiosciences), PE-Cy7 conjugated anti-CD16/32 (93; Biolegend), PE-Cy5-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-ckit (2B8) antibody, in addition to antibodies against the following PE-conjugated lineage markers: Ter119, B220 (6B2), Gr1 (8C5), Mac1 (M1/70), CD2 (RM2-5), CD3 (KT31.1) and CD8 (53-6.7). For isolation of Flt3 1 IL-7R 1 Lin 2 Sca-1 low c-kit low CLPs, bone marrow cells were incubated with PE-Cy5-conjugated anti-Flt3 (A2F10; eBiosciences), PE-conjugated anti-IL-7R (A7R34; eBiosciences), PE-Cy7-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-c-kit (2B8) antibody, in addition to antibodies against the following FITC-conjugated lineage markers: Ter119, B220 (6B2), Gr1 (8C5), Mac1 (M1/70), CD2 (RM2-5), CD3 (KT31.1) and CD8 (53-6.7). Unless otherwise noted, antibodies were obtained from Bio-Legend, BD Biosciences, or eBioscience. Biotin-conjugated antibodies were visualized using streptavidin-conjugated APC-Cy7. Haematopoietic stem cells were sometimes pre-enriched by selecting c-kit 1 cells using paramagnetic microbeads and autoMACS (Miltenyi Biotec). Nonviable cells were excluded from sorts and analyses using the viability dye 49,6-diamidino-2-phenylindole (DAPI) (1 mg ml 21 ). To analyse BrdU incorporation into haematopoietic stem cells, bone marrow cells were incubated with PE-conjugated anti-CD150 (TC15-12F12.2), FITC-conjugated anti-CD48 (HM48-1), PerCP-Cy5.5-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-c-kit (2B8) antibody, in addition to antibodies against the following FITC-conjugated lineage markers: CD41 (MWReg30), Ter119, B220 (6B2), Gr1 (8C5), CD2 (RM2-5), CD3 (KT31.1) and CD8 (53-6.7). Biotin-conjugated c-kit was visualized using streptavidin-conjugated AlexaFluor 700 or PE-Cy7 (Invitrogen). To distinguish donor haematopoietic stem cells from recipient haematopoietic stem cells, AlexaFluor 700 conjugated anti-CD45.2 (clone 104) antibody was used. To analyse haematopoietic lineage composition, bone marrow cells or splenocytes were incubated with FITC-conjugated anti-B220, PE-conjugated anti-Ter119, APC-conjugated anti-CD3, APC-eFluor780-conjugated anti-Mac1 (M1/70), and PE-Cy7-conjugated anti-Gr1 antibodies. Annexin-V staining was performed using Annexin-V APC (BD Biosciences). Flow cytometry was performed with FACSAria II, FACSCanto II, LSR II, or LSRFortessa flow-cytometers (BD Biosciences). Ki67 staining. Ki67 staining was performed as before 36 . In brief, haematopoietic stem cells were sorted into 70% ethanol and kept at 220 uC for at least 24 h. Ki67 staining was performed using a FITC Ki-67 kit (BD Biosciences), followed by staining with 50 mg ml 21 propidium iodide (Molecular Probes) and analysed by flow cytometry.
Castration. An incision was made in the scrotum and the testis and attached testicular fat pads were pulled out of the incision. Spermatochords were individually ligated with absorbable sutures (4-0 chromic gut), then excised, and then 1-3 non-absorbable sutures Tevdek II) were used to close the skin. Ovariectomy. The skin around the dorsal midline caudal to the posterior borders of the ribs was shaved and an incision was made to expose the ovaries on each side. The ovaries were isolated, ligated with absorbable sutures (4-0 chromic gut) and excised, and then 3-4 non-absorbable sutures Tevdek II) were used to close the skin. Sham-treated mice underwent similar surgeries except that the gonads were left intact. All animals were allowed to recover for 2 weeks before BrdU was administered.
Cell-cycle analysis of haematopoietic stem cells from competitively reconstituted mice. Adult recipient mice (CD45.1) were irradiated with an X-ray source delivering approximately 300 rad min 21 in two equal doses of 540 rad, delivered at least 2 h apart. 10 6 whole bone marrow cells from CD45.2 Vav1-cre; Esr1 fl/fl mice were transplanted along with 10 6 CD45.1 whole bone marrow cells from wild-type mice into the retro-orbital venous sinus of anaesthetized recipients. Fifteen weeks after transplantation, recipient mice were either treated with oil or 2 mg oestradiol for 7 days. Mice were administered BrdU continuously for the last 3 days of oestradiol treatment. BrdU incorporation into haematopoietic stem cells was analysed by flow cytometry as described above. Measurement of serum hormone concentration. Whole blood samples were collected and allowed to clot at room temperature for 90 min before being centrifuged at 2,000g for 15 min at room temperature. Serum samples were analysed for oestradiol and progesterone levels at the University of Virginia Center for Research in Reproduction. Quantitative real-time (reverse transcription) PCR. Haematopoietic stem cells and other haematopoietic cells were sorted into Trizol (Life Technologies) and RNA was isolated according to the manufacturer's instructions. cDNA was made with random primers and SuperScript III reverse transcriptase (Life Technologies). Quantitative PCR was performed using a LightCycler 480 (Roche Applied Science) or ViiA7 Real-Time PCR System (Life Technologies). Each sample was normalized to b-actin. Primers to quantify cDNA levels were Esr1 forward, 59-CCTTCTAGA CCCTTCAGTGAAGCC-39, Esr1 reverse, 59-CGAGACCAATCATCAGAATC TCC-39; Esr2 forward, 59-CCAGCCCTGTTACTAGTCCAAGC-39, Esr2 reverse, 59-GGTACACTGATTCGTGGCTGG-39, Pgr forward, 59-CCAGCTCACAGCG CTTCTACC-39, Pgr reverse, 59-GAAAGAGGAGCGGCTTCACC-39, Ar forward, 59-GGTGTGTGCCGGACATGACAAC-39, Ar reverse, 59-GGTCATCCA CATGCAAGTTGCGG-39, b-actin forward, 59-CGTCGACAACGGCTCCGG CATG-39 and b-actin reverse, 59-GGGCCTCGTCACCCACATAGGAG-39. Microarray analysis. Groups of three male and three female mice were treated with either E2 (2 mg per day) or vehicle (oil) for one week. Haematopoietic stem cells were sorted into Trizol and RNA purified according to the manufacturer's instructions. DNase-I-treated RNA samples were amplified and biotinylated using the Nugen Ovation Pico WTA V2 system and the Encore Biotin Module (NuGEN Technologies). Biotinylated samples were hybridized to Affymetrix Mouse Gene 1.0 ST Arrays (Affymetrix) by the Baylor College of Medicine Genomic and RNA profiling core. dChip software 37 was used to calculate normalized expression values for each array. Gene set enrichment analysis was performed as described previously 38 .
Haematopoietic stem-cell culture and in vitro BrdU incorporation. Haematopoietic stem cells were sorted directly into serum-free, phenol-red-free medium (X-Vivo 15, Lonza) supplemented with 50 ng ml 21 of SCF and 50 ng ml 21 TPO (both from Peprotech), with or without 100 nM oestradiol, and cultured for 3 days. BrdU (10 mM final concentration) was added for an hour before cells were cytospun to a slide. Slides were fixed with cold methanol for 5 min at 220 uC, then washed with PBS containing 0.01% NP-40 and treated with 2N HCl for 15 min. Slides were blocked in PBS containing 4% goat serum, 4 mg ml 21 BSA, and 0.1% NP-40 followed by staining overnight at 4 uC with antibody against BrdU (BU1/75, 1:100, Abcam) as described previously 36 .
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Extended Data Figure 2 | Administration of oestradiol (E2) to mice induced erythropoiesis in the spleen. a-c, Treatment of male and female mice for 1 week with E2, with or without P, did not affect the numbers of Mac1 1 /Gr1 1 myeloid cells, B220 1 B cells, or CD3 1 T cells in the bone marrow or spleen of either sex. d, E2 and E21P treatment did significantly increase the number of Ter119 1 erythroid cells in the spleen of male mice, and E2 treatment significantly increased the number of Ter119 1 erythroid cells in the spleen of female mice. n 5 3 mice per treatment in 3 independent experiments. All data represent mean 6 standard deviation; *P , 0.05; **P , 0.005; ***P , 0.0005 by Student's t-test comparing each treatment to vehicle.
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Extended Data Figure 3 | Administration of exogenous oestrogen and progesterone significantly increased serum oestrogen and progesterone levels in mice but progesterone did not affect haematopoietic stem-cell division in vivo. a, Oestradiol treatment significantly increased serum oestradiol levels in male and female mice but the increased levels remained within the physiological range, similar to levels observed during pregnancy (see Fig. 4e ) (male oil, 22; male E2, 20; female oil, 33; female E2, 14 mice used in 8 independent experiments). b, Progesterone treatment significantly increased serum progesterone levels in male and female mice (n 5 3 mice per treatment in 3 independent experiments). Note that this did not affect bone marrow or spleen cellularity, haematopoietic stem-cell frequency, or haematopoietic stem-cell division ( Fig. 2b-d) . c, Esr1-deficient mice had normal levels of serum progesterone (n 5 3 mice per group in 3 independent experiments). d-f, Administration of a progesterone receptor antagonist, RU486 (RU), did not affect bone marrow or spleen cellularity (d), haematopoietic stem-cell frequency in the bone marrow (e), or the division of haematopoietic stem cells, MPPs, or WBM cells (f). All data represent mean 6 standard deviation from Extended Data Figure 7 | Pharmacological ERa activation, but not ERb activation, is sufficient to promote haematopoietic stem-cell division. Male mice (n 5 5 mice per treatment in 3 independent experiments) were treated with oil, ERa agonist PPT, or ERb agonist DPN for 14 days then pulsed with BrdU for 10 days, beginning on the fourth day of hormone treatment. a, b, PPT or DPN treatment did not significantly affect the cellularity of bone marrow or spleen (a), or the frequencies of haematopoietic stem cells or MPPs in bone marrow (b). c, PPT treatment, but not DPN treatment, significantly increased erythropoiesis in bone marrow and spleen. d, PPT significantly increased the division rates of haematopoietic stem cells and MPPs, but DPN failed to do so, suggesting that ERa activation, but not ERb activation, promotes haematopoietic stem cell division. Data represent mean 6 standard deviation; ***P , 0.0005 by Student's t-test comparing each treatment to vehicle (oil).
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